Suppliers / KELIX bio Malta

KELIX bio Malta

Malta 70 employees Updated 9 July 2026

KELIX bio Malta is a finished-dose manufacturer based in Malta. It appears in 18 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with EMA and EDE (AE). Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 16 December 2022 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
18
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 16 December 2022 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Birzebbuga BBG3000, United Arab Emirates Not on file
Birzebbuga, Malta Not on file
Malta, Malta 3013541978

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 11 1
EDE (AE) 7 None

Comparing suppliers?

Choose your molecules and target markets. KELIX bio Malta comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 16 December 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates